Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial

This trial is testing whether the time of day that immunotherapy is given affects how well it works for advanced melanoma. Researchers want to know if morning vs. evening dosing of the drugs ipilimumab and nivolumab makes a difference in outcomes. **You may be eligible if...** - You have been diagnosed with Stage IV melanoma of the skin, hands/feet, or mucous membranes that cannot be surgically removed - You are 18 or older - You have not received immunotherapy in the past year (targeted BRAF/MEK therapies are allowed) - You are in good physical condition (ECOG 0–1) - You have small, symptom-free brain tumors (less than 2 cm) — these are allowed **You may NOT be eligible if...** - You have eye (uveal) melanoma - You are taking high-dose steroids or other immune-suppressing medications (more than 10 mg prednisone daily) - You have an active autoimmune disease that would prevent immunotherapy - Cancer has spread to the membranes covering your brain (leptomeningeal disease) Talk to your doctor to see if this trial is right for you.